MAPK1 is a protein involved in various cellular processes relevant to neurodegeneration. For detailed molecular information, refer to the References section.
[^1]
[^2]
[^3]
[^4]
[^5]
[^6]
[^7]
| MAPK1 Protein (ERK2) |
|---|
| Protein Name | Mitogen-Activated Protein Kinase 1 |
| Gene | [MAPK1](/genes/mapk1) |
| UniProt ID | [P28482](https://www.uniprot.org/uniprot/P28482) |
| PDB Structure | 1PMU, 2GPH, 4ICL |
| Molecular Weight | 41 kDa |
| Subcellular Localization | Cytoplasm, nucleus |
| Protein Family | MAP kinase family, CMGC group |
MAPK1 (ERK2) is a 41 kDa serine/threonine protein kinase consisting of 360 amino acids. The protein has a typical MAP kinase fold with a phosphorylated activation loop containing the conserved dual phosphorylation motif Thr-X-Tyr. The structure consists of two domains: a smaller N-terminal domain and a larger C-terminal domain connected by a flexible hinge region. The active site is located in the cleft between these domains.
MAPK1/ERK2 plays critical roles in neuronal function:
- Synaptic plasticity: Mediates long-term potentiation (LTP) and long-term depression (LTD)
- Neuronal differentiation: Controls neuronal progenitor cell differentiation
- Learning and memory: Essential for memory formation through CREB phosphorylation
- Axonal guidance: Regulates cytoskeletal dynamics during development
- Transcription regulation: Phosphorylates transcription factors including ELK-1, c-Fos, and CREB
Dysregulation of MAPK1 signaling is implicated in several neurodegenerative diseases:
- Alzheimer's disease: Hyperphosphorylation of ERK1/2 observed in AD brains, associated with tau pathology
- Parkinson's disease: ERK activation in dopaminergic neurons in response to mitochondrial toxins
- Amyotrophic lateral sclerosis: Altered MAPK signaling in motor neuron disease
- Huntington's disease: Dysregulated ERK/CREB signaling contributes to transcriptional deficits
- PSP/CBS: ERK activation associated with tau pathology in tauopathies
MAPK1 is a target for drug development:
- Small molecule inhibitors: Multiple ERK inhibitors in clinical trials for cancer
- Neuroprotective strategies: Modulating MAPK signaling to prevent neuronal death
- Anti-inflammatory approaches: Targeting MAPK pathways to reduce neuroinflammation
- Thomas and Huganir, MAPK cascade in NMDA receptor-dependent LTP (2004)
- Subramaniam and Unsicker, ERK signaling in neurodegeneration (2010)
- Kim and Choi, Role of MAPK in Alzheimer's disease (2015)